STVN

Stevanato GroupC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-08-07 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$21.20

Analysis reference price unavailable

Analysis 2026-08-07 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$16.50

Analysis reference price unavailable

Analysis 2026-08-07 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-07

AI commentary

The primary company release improves evidence quality and shows positive revenue, mix, margin, and adjusted-guidance trends, but the one-time divestiture charge, negative free cash flow, and engineering decline make the signal mixed rather than strongly bullish. Analyst revisions and precise post-print price reaction remain unavailable, so the memo stays a cautious monitoring view.

RankAlpha Sentiment Codex - 2026-08-07

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-08-14catalystDivestiture charge and cash-flow pressureMedium impact

The Q2 release reported €0.08 diluted EPS including €12.2 million of expenses related to the Balda C. Brewer divestiture. Q2 free cash flow was negative €32.0 million, while net debt was €360.3 million. These items may temper the positive operating read-through [#PR-EARNINGS-2026-08-04].

2026-11-05eventVerified Q2 2026 growth and updated guidanceMedium impact

Stevanato reported Q2 revenue of €302.0 million, up 8% year over year, with high-value solutions at 45% of revenue, a 28.7% gross margin, and a 26.0% adjusted EBITDA margin. Adjusted diluted EPS was €0.14. The company updated fiscal 2026 guidance to €1.260–€1.280 billion revenue, €335.0–€345.2 million adjusted EBITDA, and €0.60–€0.62 adjusted diluted EPS [#PR-EARNINGS-2026-08-04]. The report date was previously announced for August 4, 2026 [#PR-EARNINGS-2026-07-21].

2027-08-07catalystHigh-value solutions and capacity investmentHigh impact

High-value solutions revenue increased 16% year over year to €135.9 million, and Q2 capital expenditures included new plants in Italy and Indiana plus the Alina pen-injector program in Germany. This provides a concrete longer-term operating driver, though execution and capital intensity remain important monitors [#PR-EARNINGS-2026-08-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-07 • Updated nightlySource: Internal modelMethodology